このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer (VIRAGE2)

2026年7月24日 更新者:Theriva Biologics SL

A Phase IIa, Single-arm, Single-center, Open Label, Proof-of-concept Trial Evaluating Increased Frequency Dosing of VCN-01 (Zabilugene Almadenorepvec) in Combination With Nab-Paclitaxel/Gemcitabine (GnP) in Patients With Newly-Diagnosed Metastatic Pancreatic Cancer

The goal of this clinical trial is to learn if the new administration regimen of VCN-01, given together with the standard chemotherapy drugs gemcitabine and nab-paclitaxel (GnP), is safe and well tolerated. The behaviour of VCN-01 in the organism will be assessed, together with the possible benefits of this administration regimen. This study includes adults with newly diagnosed pancreatic ductal adenocarcinoma (PDAC) that has spread to other parts of the body (stage IV) and who have not received prior treatment for pancreatic cancer.

Participants will receive three planned doses of VCN-01, given once every 56 days. Each dose of VCN-01 is followed one week later by two cycles of standard chemotherapy with gemcitabine and nab-paclitaxel. Participants will be monitored throughout the study for safety and side effects.

調査の概要

状態

募集

条件

介入・治療

研究の種類

介入

入学 (推定)

6

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Madrid
      • Madrid、Madrid、スペイン、28041
        • 募集
        • Hospital 12 de Octubre
        • コンタクト:
          • Victoria López, Study Coordinator
          • 電話番号:452750 +34 91 390 8950
          • メール:rcarbonero@gmail.com
        • 主任研究者:
          • Rocío García Carbonero, Dr

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Written informed consent obtained prior to initiating any trial-specific procedures or assessments.
  • Male or female patients aged 18 years or over.
  • Patients with histologically or cytologically confirmed pancreatic adenocarcinoma that is metastatic (stage IV) at diagnosis and who have not received any treatment for their pancreatic cancer.
  • Patients must be able to receive their first dose of VCN-01 ≤6 weeks after their metastatic pancreatic cancer diagnosis.
  • Patients must have at least one measurable tumor lesion that can be imaged for assessments according to RECIST 1.1.
  • ECOG performance status of 0 or 1 at enrollment.
  • Must be willing to comply with the trial intervention, including prophylactic medications, and procedures.
  • Adequate baseline organ function (hematologic, liver, renal) within the 7 days prior to enrollment:

Hematology:

  • Leukocytes ≥3.0x103 mcL
  • Absolute neutrophil count ≥1.5x10⁹/L
  • Hemoglobin ≥9 g/dL
  • Platelets ≥100x10⁹/L

Coagulation:

  • Prothrombin time or international normalized ratio ≤1x upper limit of normal (ULN)
  • Activated partial thromboplastin time ≤1.2xULN

Hepatic:

  • Total bilirubin ≤1.5xULN
  • ALT and AST ≤2.5xULN (<5xULN is acceptable if liver metastases are present)

Renal:

  • Serum creatinine ≤1.5xULN; or,
  • If serum creatinine >1.5xULN, an estimated creatinine clearance >50 mL/min using the Cockcroft and Gault formula

Nutritional:

• Serum Albumin ≥30 g/L

- Adequate left ventricular ejection fraction (LVEF) ≥ 50% measured by ECHO or MUGA and QT interval corrected by Fridericia (QTcF) assessment ≤ 450 ms for men or ≤ 470 ms for women.

Exclusion Criteria:

  • Unwillingness to complete the trial procedures for geographic, psychiatric, or social reasons.
  • Patient has previously received treatment for their metastatic pancreatic cancer with surgery, radiotherapy, chemotherapy or investigational therapy; except that:
  • Palliative radiotherapy for pain is permitted;
  • Placement of a biliary stent/tube is permitted.
  • Patients who, in the opinion of the investigator, have symptoms or signs suggesting clinically unacceptable deterioration during the Screening Period.
  • Active infection or other serious illness or autoimmune disease at the moment of enrollment. Active infection includes:

    • Tuberculosis (TB; clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice.

  • Patients with past or resolved TB are eligible to participate.

    • Hepatitis B Virus (HBV; positive HBV surface antigen [HBsAg] result).

  • HBV carriers (patients positive for HBsAg without an active infection) are not eligible to participate;
  • Patients requiring antiviral medicines for HBV prophylaxis or treatment are not eligible to participate;
  • Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBcAb] and absence of HBsAg) are eligible to participate provided that blood HBV DNA is negative at enrollment.

    • Hepatitis C Virus (HCV; positive HCV Ribonucleic acid [RNA]).

  • Patients requiring antiviral medicines for HCV prophylaxis or treatment are not eligible to participate;
  • Patients positive for HCV antibody are eligible to participate (only if polymerase chain reaction is negative for HCV RNA).

    • Human immunodeficiency virus (positive HIV 1/2 antibodies)

Active infection or other serious illness or autoimmune disease at the moment of enrollment. Active infection includes:

  • Tuberculosis (TB; clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice.

    - Patients with past or resolved TB are eligible to participate.

  • Hepatitis B Virus (HBV; positive HBV surface antigen [HBsAg] result).

    • HBV carriers (patients positive for HBsAg without an active infection) are not eligible to participate;
    • Patients requiring antiviral medicines for HBV prophylaxis or treatment are not eligible to participate;
    • Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBcAb] and absence of HBsAg) are eligible to participate provided that blood HBV DNA is negative at enrollment.
  • Hepatitis C Virus (HCV; positive HCV Ribonucleic acid [RNA]).

    • Patients requiring antiviral medicines for HCV prophylaxis or treatment are not eligible to participate;
    • Patients positive for HCV antibody are eligible to participate (only if polymerase chain reaction is negative for HCV RNA).
  • Human immunodeficiency virus (positive HIV 1/2 antibodies)

    • Known chronic liver disease (e.g. liver cirrhosis, liver fibrosis, chronic hepatitis); except that:
    • Patients with fatty liver disease are eligible to participate if their liver transaminases meet inclusion criterion 8.
    • Concurrent malignant hematologic or solid disease; except that:
    • Patients with a prior history of cancer are eligible to participate if they are in complete remission from their prior cancer for at least 3 years.
    • Patients with Li Fraumeni syndrome or with previously known retinoblastoma protein pathway germline deficiency.
    • Patients with untreated brain metastases and/or leptomeningeal carcinomatosis with progressive symptoms despite corticosteroid coverage; except that:
    • Patients with brain metastases with stable symptoms are eligible to participate.
    • Patients with previous pneumonitis or interstitial lung disease.
    • Patients with pre-existing sensory neuropathy >G1
    • Clinical evidence of deep vein thrombosis, pulmonary embolism or arterial thromboembolic event during the Screening Period.
    • Patients with superficial vein thrombosis are eligible to participate.
    • Patients with uncontrolled coagulopathy.
    • Any other condition, disease, metabolic dysfunction (e.g., uncontrolled diabetes mellitus), active or uncontrolled infection/inflammation, physical examination finding, mental state or clinical laboratory finding that would contraindicate participation in the clinical trial due to concerns over safety or potential non-compliance with clinical trial procedures.
    • A female patient, who is pregnant or lactating.
    • Female patients of reproductive potential must agree to use a highly effective method of birth control. Male patients must agree to use condoms.
    • Treatment with live attenuated vaccines in the last 3 weeks before the administration of the IMP.
    • Treatment with an adenovirus type-5 (Ad5)-based COVID-vaccine in the last 12 weeks before the administration of the IMP.
    • Treatment with another investigational agent within five of that investigational agent's half-lives prior to the administration of the IMP.
    • Chronic immunosuppressive therapy; except that:
    • Inhaled corticosteroids are permitted;
    • Oral or IV corticosteroids with a dose lower than 10 mg prednisone or equivalent/day are permitted;
    • Dexamethasone up to a maximum dose of 1 mg/day is permitted.
    • Known allergy or hypersensitivity to any of the trial-specific interventions or any of their excipients.
    • Subjects, for whom first line treatment options other than the combination nab-paclitaxel/gemcitabine are recommended by the investigator.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:High dose
The initial dosing regimen for this study comprises three "macrocycles", each of which comprises one dose of VCN-01 followed one week later by 2 cycles of GnP according to standard of care
The initial dosing regimen for this study comprises up to three "macrocycles", each of which comprises one dose of VCN-01 followed one week later by 2 cycles of GnP according to standard of care (SoC)
IV nab-paclitaxel (starting dose 125 mg/m²) followed by IV gemcitabine (starting dose 1,000 mg/m²) according to SoC clinical practice (GnP SoC). Dose modifications and interruptions permitted per prescribing information/SmPC.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Pharmacokinetics (PK) of VCN-01
時間枠:From enrollment up to 30 days from the last dose of study intervention
VCN-01 concentration in blood at predefined time points.
From enrollment up to 30 days from the last dose of study intervention
Incidence of Treatment-Emergent Adverse Events
時間枠:From enrolment up to 30-days from the last dose of study intervention
Frequency and proportion of participants experiencing AEs/SAEs; descriptive statistics for laboratory values.
From enrolment up to 30-days from the last dose of study intervention

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年8月3日

一次修了 (推定)

2027年8月1日

研究の完了 (推定)

2027年12月1日

試験登録日

最初に提出

2026年7月8日

QC基準を満たした最初の提出物

2026年7月8日

最初の投稿 (実際)

2026年7月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月27日

QC基準を満たした最後の更新が送信されました

2026年7月24日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • P-VCNA-004

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。